Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study to determine reporting rate for hemorrhagic and thrombotic adverse drug reactions with emicizumab and replacement extended half-life FVIII products using EudraVigilance database

Next Previous
Trial Profile

A study to determine reporting rate for hemorrhagic and thrombotic adverse drug reactions with emicizumab and replacement extended half-life FVIII products using EudraVigilance database

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Feb 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emicizumab (Primary) ; Damoctocog alfa pegol; Efmoroctocog alfa; Rurioctocog alfa pegol
  • Indications Haemophilia A
  • Focus Adverse reactions

Most Recent Events

  • 16 Jan 2023 Results of an analysis reporting rate of hemorrhagic ADR vs a higher reporting rate of thrombotic ADR for emicizumab published in the Journal of Thrombosis and Haemostasis
  • 12 Jan 2023 New trial record
  • 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top